🧠 Trigeminal Neuralgia Carbamazepine Response Simulator

Baseline Trigeminal Hyperexcitability

A hyperexcitable trigeminal nerve fires severe pain from the lightest facial touch.

• <2 min: Attack Duration (seconds to ~2 minutes)
• Electric: Pain Descriptor (shock-like, stabbing)
• V2 / V3: Most Affected Branch (maxillary & mandibular)
• Very Low: Trigger Threshold (light touch suffices)

Ectopic nerve firing

Compressed or demyelinated fibers fire spontaneous, exaggerated signals.

Trigger-zone touch

Innocuous stimuli near the mouth/nose provoke a full pain paroxysm.

Refractory period

A brief pain-free window follows each attack before re-triggering.

Trigger Zone Identification

Clinicians gently probe the face to map exact trigger-zone locations.

• 2–3: Common Sites (nasolabial fold, lip)
• Light Touch: Mapping Method (cotton wisp test)
• Unilateral: Side Involved (nearly always one side)
• High: Diagnostic Value (confirms TN pattern)

Zone localization

Hotspots cluster along V2 territory around nose and upper lip.

Branch correlation

Zone location predicts which nerve division is involved.

Baseline severity

Mapping sets a pre-treatment reference for tracking response.

Carbamazepine — Sodium Channel Blockade

Carbamazepine binds voltage-gated Na⁺ channels, damping runaway firing.

• Anticonvulsant: Drug Class (Na⁺ channel blocker)
• 100–200 mg: Starting Dose (twice daily typical)
• Days: Onset of Relief (partial early response)
• Nav1.x: Channel Target (use-dependent block)

Use-dependent block

Drug preferentially blocks channels firing rapidly and repeatedly.

Reduced excitability

Fewer open channels means fewer ectopic action potentials.

Early titration care

Low starting dose limits sedation while relief begins.

Dose Titration to Therapeutic Level

Dose climbs gradually over days to weeks toward effective blockade.

• 600–1200: Target Range (mg/day typical)
• ~100–200: Titration Pace (mg increase per step)
• Levels + CBC: Monitoring (labs during titration)
• ~1–2 wks: Time to Steady State (autoinduction settles)

Gradual escalation

Slow increases balance pain control against side effects.

Autoinduction

Carbamazepine speeds its own metabolism over the first weeks.

Response tracking

Attack frequency and trigger sensitivity fall as dose rises.

Pain Control & Trigger Desensitization

Most patients reach major attack reduction with tolerable side effects.

• ~70–80%: Responders (significant relief)
• Marked: Attack Reduction (from daily to rare)
• Normalized: Trigger Sensitivity (much less provocative)
• Maintenance: Long-term Plan (lowest effective dose)

Excitability normalizes

Sustained blockade lets nerve firing thresholds recover.

Trigger zones fade

Previously provocative touch no longer reliably triggers pain.

Ongoing management

Some patients need dose adjustment or second-line options later.